SARM
RAD-140 (Testolone)
SaveA potent non-steroidal SARM developed by Radius Health, notable for a high anabolic-to-androgenic ratio in preclinical models. Phase I data exists in breast cancer.
Quick verdict
High preclinical potency but very limited human data. Reports of liver toxicity in case series raise safety concerns.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Preclinical data shows strong anabolic activity with relative prostate sparing. A Phase I trial in ER+/AR+ metastatic breast cancer assessed safety and preliminary efficacy. Multiple published case reports document drug-induced liver injury in recreational users.
Benefits
- High anabolic-to-androgenic ratio in animals
- Strong preclinical muscle and bone data
- Neuroprotective effects observed in vitro
Dosage notes
No established safe dose for healthy humans. Phase I cancer trial used 50–150 mg/day.
Side effects
- Liver toxicity (case reports)
- Severe testosterone suppression
- Aggression
Who should be cautious
Multiple case reports of serious liver injury. Potent hormonal suppression expected. WADA-banned. Not approved for any use.
What this page cannot tell you
The only human trial is in metastatic breast cancer — not in healthy or muscle-wasting populations. Liver toxicity reports are concerning.
Leaderboard scores
- Muscle50
- Recovery25
Write a review
Sign in to write a review.